Our review of recent preliminary and published data from clinical trials revealed that obese asthmatics respond favorably to dupilumab, mepolizumab, omalizumab, and tezepelumab, which are biologics currently indicated as add-on maintenance therapy for severe asthma. Furthermore, clinical trials are ongoing to assess the efficacy of non-biologics in the treatment of obese asthma, including a glucagon-like peptide-1 receptor agonist, a Janus kinase inhibitor, and probiotics. Although many biologics presently indicated as add-on maintenance therapy for severe asthma exhibit efficacy in obese asthmatics, other phenotypes of asthma co-existing with obesity may be refractory to these medications. Thus, to improve quality of life and asthma control, it is imperative to identify therapeutic options for all existing phenotypes of obese asthma.
Keyphrases
- weight loss
- metabolic syndrome
- chronic obstructive pulmonary disease
- lung function
- clinical trial
- type diabetes
- adipose tissue
- allergic rhinitis
- insulin resistance
- bariatric surgery
- rheumatoid arthritis
- obese patients
- cystic fibrosis
- randomized controlled trial
- magnetic resonance imaging
- high fat diet induced
- computed tomography
- single cell
- deep learning
- skeletal muscle